Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chee Khoon Lee

Showing results (11-20 of 86) with videos related to

Pageof 9
Sort By:
Acta Oncologica (Stockholm, Sweden)|October 15, 2019
Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials - an empirical analysis of biasKelli Snyders, Doah Cho, Jun Hee Hong, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2026
Informative censoring in maintenance therapy trials for advanced ovarian cancer: An empirical assessment of its impact on treatment benefitRachel Woodford, Sally Lord, Annelise Decaria, et al.
The Oncologist|July 24, 2025
Under the radar-frequency, timing, duration and trajectory of lower grade adverse events in clinical trials of anti-cancer therapiesKatherine E Francis, Sarah J Lord, Sandy Simon, et al.
Future Oncology (London, England)|February 18, 2026
Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancerRachel Woodford, Sally Lord, Tom John, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2016
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-AnalysisChee Khoon Lee, Johnathan Man, Sally Lord, et al.
European Journal of Cancer (Oxford, England : 1990)|June 2, 2022
Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysisSandy Simon, Katherine E Francis, Janene E Dalrymple, et al.
JCO Precision Oncology|February 17, 2022
Clinical Equipoise for Trials of Novel Biologic Therapies, Therapeutic Success Rates, and Predictors of Success: A Meta-AnalysisDoah Cho, Felicia T Roncolato, Johnathan Man, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2012
Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimusChee Khoon Lee, Ian C Marschner, R John Simes, et al.
Therapeutic Advances in Medical Oncology|August 11, 2018
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysisKatrin M Sjoquist, Sarah J Lord, Michael L Friedlander, et al.
Journal of Geriatric Oncology|June 13, 2021
Are clinical trial eligibility criteria representative of older patients with lung cancer? A population-based data linkage studyMonica Tang, Sallie-Anne Pearson, Andrea L Schaffer, et al.
Pageof 9

Showing results (11-20 of 86) with videos related to

Sort By:
Pageof 9
Acta Oncologica (Stockholm, Sweden)|October 15, 2019
Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials - an empirical analysis of biasKelli Snyders, Doah Cho, Jun Hee Hong, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2026
Informative censoring in maintenance therapy trials for advanced ovarian cancer: An empirical assessment of its impact on treatment benefitRachel Woodford, Sally Lord, Annelise Decaria, et al.
The Oncologist|July 24, 2025
Under the radar-frequency, timing, duration and trajectory of lower grade adverse events in clinical trials of anti-cancer therapiesKatherine E Francis, Sarah J Lord, Sandy Simon, et al.
Future Oncology (London, England)|February 18, 2026
Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancerRachel Woodford, Sally Lord, Tom John, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2016
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-AnalysisChee Khoon Lee, Johnathan Man, Sally Lord, et al.
European Journal of Cancer (Oxford, England : 1990)|June 2, 2022
Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysisSandy Simon, Katherine E Francis, Janene E Dalrymple, et al.
JCO Precision Oncology|February 17, 2022
Clinical Equipoise for Trials of Novel Biologic Therapies, Therapeutic Success Rates, and Predictors of Success: A Meta-AnalysisDoah Cho, Felicia T Roncolato, Johnathan Man, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2012
Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimusChee Khoon Lee, Ian C Marschner, R John Simes, et al.
Therapeutic Advances in Medical Oncology|August 11, 2018
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysisKatrin M Sjoquist, Sarah J Lord, Michael L Friedlander, et al.
Journal of Geriatric Oncology|June 13, 2021
Are clinical trial eligibility criteria representative of older patients with lung cancer? A population-based data linkage studyMonica Tang, Sallie-Anne Pearson, Andrea L Schaffer, et al.
Pageof 9